Skip to content

A Clinical Study of Transaxillary Endoscopic and Open Thyroidectomy for PTC

A Multicenter, Randomized, Controlled Clinical Study on the Feasibility and Safety of Gasless Transaxillary Posterior Endoscopic and Open Thyroidectomy for Papillary Thyroid Cancer.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05545852
Enrollment
290
Registered
2022-09-19
Start date
2021-06-01
Completion date
2025-05-31
Last updated
2023-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary Thyroid Cancer

Keywords

endoscopic, thyroidectomy

Brief summary

To evaluate the feasibility and safety of gasless transaxillary posterior endoscopic thyroidectomy (Resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) and open radical thyroidectomy (Resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) as the current standard surgical treatment mode in terms of feasibility and safety of radical thyroidectomy.

Detailed description

Subjects that suffering from papillary thyroid carcinoma will be randomized into Study Group (gasless transaxillary posterior endoscopic thyroidectomy ) or Control Group (conventional open thyroidectomy). Measure the outcomes as following, early complication rate, life quality score, the number of dissected lymph nodes, the volume of residual gland, 3-year recurrence rate, operation duration, hospital stays, hospitalization expense, and inflammatory and immune response.

Interventions

PROCEDUREGTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)

Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection

PROCEDURECOT(Conventional Open Thyroidectomy)

Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* The patient's informed consent; * 18 years old \< age \< 70 years old; * Papillary thyroid carcinoma (Bethesda grade V-VI) was pathologically diagnosed by fine needle aspiration biopsy of the primary thyroid tumor before surgery; * Color Doppler TI-RADS 4c-5 of primary thyroid tumor; * The preoperative clinical staging is T1, N0-1a, M0 (see diagnostic criteria for details; according to AJCC-8th TNM tumor staging); * It is expected that R0 surgical results can be obtained by performing single thyroid lobectomy and isthmus resection + ipsilateral central lymph node dissection; * Preoperative ASA score I-III.

Exclusion criteria

* Pregnant or lactating patients; * Suffering from serious mental illness; * Preoperative imaging examinations suggest that the tumor is located in the thyroid isthmus or involves bilateral lobes; * Preoperative imaging examinations suggest the possibility of cervical lateral lymph node or distant metastasis; * Hashimoto's thyroiditis combined with hyperthyroidism or abnormal thyroid function; * History of neck surgery; * History of thyroid surgery (including ablation therapy for thyroid nodules); * Family history of thyroid cancer; * History of childhood ionizing radiation exposure; * History of other malignant diseases within 5 years; * A history of unstable angina or myocardial infarction within 6 months; * History of cerebral infarction or cerebral hemorrhage within 6 months; * History of continuous systemic corticosteroid therapy within 1 month; * Concurrent surgical treatment of other diseases is required; * Patients who are judged by the investigator to be unsuitable to participate in this trial.

Design outcomes

Primary

MeasureTime frameDescription
Early complication rate30 days after surgeryEarly complications include hemorrhage, surgical site infection, recurrent laryngeal nerve injury, hypoparathyroidism (PTH\<15pg/ml, or showing hypocalcification symptoms), chyle leakage, trachea injury, esophageal injury, etc.
Life quality score (3 days after surgery)3 days after surgeryUse a modified Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QOL) to measure the quality of life 3 days after surgery.
Life quality score (1 month after surgery)1 month after surgeryUse a modified Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QOL) to measure the quality of life 1 month after surgery.
Life quality score (3 months after surgery)3 months after surgeryUse a modified Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QOL) to measure the quality of life 3 months after surgery.
Life quality score (6 months after surgery)6 months after surgeryUse a modified Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QOL) to measure the quality of life 6 months after surgery.
Life quality score (1 year after surgery)1 year after surgeryUse a modified Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QOL) to measure the quality of life 1 year after surgery.

Secondary

MeasureTime frameDescription
The number of dissected lymph nodes3 days after surgeryRecord the number of harvest and metastatic lymph nodes.
Inflammatory response1 day after surgeryExamine the white blood cell count (WBC), neutrophil count (NEU) and c-reactive protein (CRP) 1 day after surgery.
The volume of residual gland6 month after surgeryMeasure the volume of residual gland with ultrasound tests.
3-year recurrence rate3 years after surgeryThe rate will be calculated from the day of randomization to the present of evidence of recurrence.
Operation durationIntraoperativeRecord the time from skin discission to incision close.
Hospital stays3 days after surgeryRecord the days from the day of surgery to the day of discharge.
Hospitalization expense3 days after surgeryThe total hospitalization expense.

Countries

China

Contacts

Primary ContactBaihui Sun, Dr.
sunbh_nfyy@163.com+8602062787170

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026